Key Highlights
- Oracle introduced Life Sciences AI Agents for clinical trial operations.
- Early access covers portfolio monitoring, trial planning and trial conduct.
- The agents can flag operational issues and suggest responses for human review.
- Oracle plans to extend the tools to other stages of clinical development.
Oracle (NYSE:ORCL) introduced Life Sciences AI Agents on November 18 to help trial teams monitor studies and coordinate operational responses. The company opened access to early adopters across three areas: portfolio monitoring, trial planning and trial conduct. The product combines information from Oracle's life sciences applications and supported outside data sources. People review and approve any proposed action before it is carried out.
Monitoring clinical trial operations
Oracle designed the agents to bring information from several operational systems together for clinical teams. One example in the announcement involves monitoring study performance and identifying possible reasons why a key performance indicator has diverged from its target. The agent can then suggest an operational response that follows the trial protocol and present it to the team for review.
The initial scope spans a portfolio of studies as well as planning and conduct for individual trials. Portfolio monitoring lets teams examine operational performance across studies, while planning and conduct cover work on setting up and running trials. Oracle grouped these three functions within the first release. It described the product as a way to coordinate operational work across teams and applications that already contribute data to the research process.
Review and approval stay with trial teams
Oracle's announced workflow separates the identification of an operational issue from the authority to act. The software can assemble information about an issue and propose a response. A person reviews that recommendation and decides whether to approve it before execution. The company described human review and authorization as part of the product's design.
The example Oracle gave shows where those controls apply. After monitoring a study and identifying a possible source of a performance variance, an agent can suggest an action consistent with the protocol. The proposal then goes to the responsible team. Oracle said the workflow is designed to help teams coordinate a response across the applications and groups involved in clinical development.
Initial access and planned additions
Oracle made the agents available to early adopters on the announcement date. The release described the operating tasks in scope and did not specify pricing, customer numbers or the schedule for general availability. Oracle directed interested organizations to its Life Sciences site for further information about availability. The company already supplies cloud applications and related services to organizations engaged in pharmaceutical research and clinical development.
The announced development plans include clinical data management, analysis after trials and workflows after a product enters the market. Oracle also listed trial design among the areas it plans to add. Each of those areas is separate from the initial remit of portfolio monitoring, planning and trial conduct. Oracle gave no release dates for the additional capabilities.
In September, Oracle separately reported FY2027 first-quarter cloud applications Revenue of USD 4.2 billion, up 10% year over year. Total cloud revenue was USD 11.6 billion, including USD 7.4 billion from cloud infrastructure. Those company-wide figures cover Oracle's cloud Business before the November launch. The early-access announcement did not break out revenue from the new life sciences agents.
What the early release covers
The first group of users can use the agents to review study activity, investigate possible operational issues and consider proposed responses within existing clinical workflows. Oracle has set out a broader roadmap for the software, while the functions announced for immediate use remain centered on trial operations. Human review and approval apply to the action recommendations in that initial scope.






Please wait processing your request...